Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients

被引:11
作者
Otani, K
Tybring, G
Mihara, K
Yasui, N [1 ]
Kaneko, S
Ohkubo, T
Nagasaki, T
Sugawara, K
机构
[1] Hirosaki Univ Hosp, Dept Neuropsychiat, Hirosaki, Aomori 036, Japan
[2] Hirosaki Univ Hosp, Dept Pharm, Hirosaki, Aomori, Japan
[3] Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Div Clin Pharmacol, S-14186 Huddinge, Sweden
关键词
mianserin; trazodone; CYP2D6;
D O I
10.1007/s002280050391
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The correlations between steady-state plasma concentrations of mianserin and its active metabolite desmethylmianserin and those of trazodone and its active metabolite m-chlorophenylpiperazine (m-CPP) were examined in 19 depressed patients. Methods: Ten patients received first mianserin (30 mg per day) and second trazodone (150 mg per day), while 9 patients received these treatments in the opposite sequence, with at least 2-week intervals between the two phases. Blood was sampled at steady state, 1-3 weeks after initiation of each treatment. Plasma concentrations of mianserin, the separate enantiomers S(+)- and R(-)-mianserin, desmethylmianserin, trazodone and m-CPP were measured by means of high-performance liquid chromatography. Results: There was a significant correlation between steady-state plasma concentrations of trazodone and total mianserin (r = 0.59) or S(+)-mianserin (r = 0.57), but not R(-)-mianserin (r = 0.33). Conclusion: The present study thus suggests that the metabolic capacity of mianserin, especially the more active S(+)-enantiomer, and that of trazodone correlate to each other. This finding supports the previous suggestions that cytochrome P4502D6 is involved in the metabolism of mianserin and trazodone.
引用
收藏
页码:347 / 349
页数:3
相关论文
共 21 条
[11]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF TRAZODONE AND 1-M-CHLOROPHENYLPIPERAZINE WITH ULTRAVIOLET AND ELECTROCHEMICAL DETECTOR [J].
OHKUBO, T ;
OSANAI, T ;
SUGAWARA, K ;
ISHIDA, M ;
OTANI, K ;
MIHARA, K ;
YASUI, N .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1995, 47 (04) :340-344
[12]   Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine [J].
Otani, K ;
Ishida, M ;
Kaneko, S ;
Mihara, K ;
Ohkubo, T ;
Osanai, T ;
Sugawara, K .
THERAPEUTIC DRUG MONITORING, 1996, 18 (02) :164-167
[13]   IS THERE A THERAPEUTIC WINDOW FOR PLASMA-CONCENTRATION OF MIANSERIN PLUS DESMETHYLMIANSERIN [J].
OTANI, K ;
KANEKO, S ;
SASA, H ;
KONDO, T ;
FUKUSHIMA, Y .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1991, 6 (03) :243-248
[14]   TRAZODONE TREATMENT INCREASES PLASMA PROLACTIN CONCENTRATIONS IN DEPRESSED-PATIENTS [J].
OTANI, K ;
YASUI, N ;
SUGAWARA, K ;
KANEKO, S ;
ISHIDA, M ;
OHKUBO, T ;
OSANAI, T ;
SUGAWARA, K ;
FUKUSHIMA, Y .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (02) :115-117
[15]  
PINDER RM, 1983, BR J CLIN PHARM, V15
[16]   LYMPHOCYTE MICROSOMAL EPOXIDE HYDROLASE IN PATIENTS ON CARBAMAZEPINE THERAPY [J].
PIRMOHAMED, M ;
ALLOTT, R ;
GREEN, VJ ;
KITTERINGHAM, NR ;
CHADWICK, D ;
PARK, BK .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (06) :577-581
[17]   PHENOTYPIC CONSISTENCY IN HYDROXYLATION OF DESMETHYLIMIPRAMINE AND DEBRISOQUINE IN HEALTHY-SUBJECTS AND IN HUMAN-LIVER MICROSOMES [J].
SPINA, E ;
BIRGERSSON, C ;
VONBAHR, C ;
ERICSSON, O ;
MELLSTROM, B ;
STEINER, E ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) :677-682
[18]   DEBRISOQUINE OXIDATION PHENOTYPE DURING NEUROLEPTIC MONOTHERAPY [J].
SPINA, E ;
MARTINES, C ;
CAPUTI, AP ;
COBALEDA, J ;
PINAS, B ;
CARRILLO, JA ;
BENITEZ, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 41 (05) :467-470
[19]   DETERMINATION OF MIANSERIN AND METABOLITES IN PLASMA BY LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
SUCKOW, RF ;
COOPER, TB ;
QUITKIN, FM ;
STEWART, JW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (08) :889-892
[20]   ENANTIOSELECTIVE DETERMINATION OF MIANSERIN AND ITS DESMETHYL METABOLITE IN PLASMA DURING TREATMENT OF DEPRESSED JAPANESE PATIENTS [J].
TYBRING, G ;
OTANI, K ;
KANEKO, S ;
MIHARA, K ;
FUKUSHIMA, Y ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1995, 17 (05) :516-521